Medroxyprogesterone (Provera) in Women's HRT: Dosing, Risks, and How It Compares to Other Progestogens

What Is Medroxyprogesterone Acetate and Why Is It Used in HRT?

Medroxyprogesterone acetate (MPA) is a synthetic progestogen derived from progesterone. In hormone replacement therapy, its job is narrow but medically necessary: it prevents estrogen from stimulating unchecked growth of the uterine lining. Women who still have a uterus and take estrogen without a progestogen face a 2- to 12-fold increased risk of endometrial cancer depending on dose and duration; adding MPA eliminates that excess risk almost entirely.

Provera, the most recognizable MPA brand, has been prescribed since FDA approval in 1959. It is also the progestogen component in the combined pill Prempro (conjugated equine estrogens 0.625 mg plus MPA 2.5 mg), the product studied in the landmark Women's Health Initiative (WHI) combined-hormone arm. Because MPA is inexpensive and highly effective at protecting the endometrium, it remains one of the most widely prescribed progestogens globally, though prescribing patterns in the United States have shifted substantially toward body-identical micronized progesterone since the WHI results were published in 2002 [1].

The North American Menopause Society (NAMS) states in its 2022 position statement: "The type of progestogen used in combination with estrogen appears to influence the breast cancer risk, with micronized progesterone showing a more favorable profile than synthetic progestogens such as MPA in observational studies." [2]

Approved Doses for HRT

MPA is prescribed in two broad regimens, and the choice between them depends on whether a woman has completed menopause and how she tolerates cyclic bleeding.

Continuous-combined regimen. MPA 2.5 mg is taken daily alongside continuous estrogen. Breakthrough bleeding is common in the first three to six months but typically resolves. This regimen is preferred for women who are at least 12 months past their last natural period, because the endometrium has already thinned and cyclic bleeding is not expected [3].

Sequential (cyclic) regimen. MPA 5 mg to 10 mg is taken for 12 to 14 days each month while estrogen continues daily. This produces a scheduled withdrawal bleed at the end of each progestogen phase. Endometrial protection requires at least 12 days of progestogen per cycle; studies using only 10 days showed residual endometrial proliferation in a subset of patients [3].

The FDA-approved prescribing information for Provera specifies 5 to 10 mg for 12 to 14 consecutive days per month when used with estrogen therapy to prevent endometrial hyperplasia [4]. Doses below 5 mg in a sequential regimen have not been shown to provide adequate endometrial protection across the full range of estrogen doses in use.

The WHI Trial: What the Data Actually Show About MPA

The WHI combined-hormone trial is the most-cited dataset on MPA risk, and it is frequently misread. The study randomized 16,608 postmenopausal women with a uterus to conjugated equine estrogens 0.625 mg plus MPA 2.5 mg (Prempro) or placebo. After a mean 5.6 years of follow-up, the hazard ratio for invasive breast cancer was 1.26 (95% CI 1.00, 1.59), meaning roughly 26 more cases per 10,000 women-years compared with placebo [1].

Three points are clinically essential when interpreting this finding.

First, the trial used oral conjugated equine estrogens paired with MPA specifically. It did not test transdermal estradiol, lower estrogen doses, micronized progesterone, or shorter durations.

Second, WHI participants had a mean age of 63 years and were an average of 13 years past menopause at enrollment. This population differs substantially from the perimenopausal woman in her early 50s who is the typical HRT candidate today.

Third, the estrogen-only WHI arm (conjugated estrogens without MPA, for women who had undergone hysterectomy, N=10,739) did not show a significant increase in breast cancer risk at 7.2 years. The HR was 0.80 (95% CI 0.62, 1.04), numerically favoring estrogen alone [5]. This difference between the two arms is a primary reason researchers and prescribers now focus attention on the progestogen component rather than estrogen alone.

MPA vs. Micronized Progesterone: Key Differences

Body-identical micronized progesterone (brand name Prometrium in the U.S., 100 mg and 200 mg capsules) has replaced MPA as the progestogen of first choice in many practices. The shift is grounded in several datasets.

The E3N cohort study (N=80,377 French women, over 8 years of follow-up) found that estrogen combined with micronized progesterone was associated with no significant increase in breast cancer risk (RR 1.00 to 95% CI 0.83, 1.22), while estrogen combined with synthetic progestogens including MPA showed RR 1.69 (95% CI 1.50, 1.91) [6].

The KEEPS trial (Kronos Early Estrogen Prevention Study, N=727, mean age 52.7 years) compared oral conjugated estrogens plus oral progesterone 200 mg against transdermal estradiol 0.05 mg patch plus progesterone 200 mg versus placebo over 4 years. Neither active arm produced a significant change in carotid intima-media thickness, but the transdermal arm showed no increase in triglycerides and no measurable hepatic first-pass effect, underscoring the metabolic differences between oral and transdermal estrogen routes [7].

There are legitimate reasons to still prescribe MPA. Prometrium capsules contain peanut oil and are contraindicated in women with peanut allergy. MPA is available as a generic at low cost, relevant when insurance coverage is limited. Some women do not tolerate micronized progesterone's sedative effect (it works partly through GABA-A receptor activity, causing drowsiness in a subset of patients). For these women, a low-dose synthetic progestogen may be the better clinical fit.

HealthRX Progestogen Selection Framework (for prescriber review):

| Patient Factor | Preferred Progestogen | |---|---| | No peanut allergy, tolerates mild sedation | Micronized progesterone 200 mg (sequential) or 100 mg (continuous) | | Peanut allergy | MPA 2.5 to 5 mg or norethindrone acetate 0.5 mg | | Cost is primary concern, generic required | MPA 2.5 to 10 mg | | History of severe PMS or PMDD | Micronized progesterone (fewer androgenic side effects) | | Prior endometrial hyperplasia on low-dose progestogen | MPA 5 to 10 mg sequential, minimum 14 days |

This framework is intended as a starting point for prescriber discussion, not a substitute for individual clinical judgment.

Estrogen Delivery Options That Pair With MPA or Micronized Progesterone

The progestogen is only half of combination HRT. The estrogen component comes in four main delivery formats for systemic therapy, each with distinct pharmacokinetics.

Oral Estradiol

Oral estradiol 0.5 mg, 1 mg, and 2 mg tablets are the lowest-cost systemic option and are familiar to most patients who are comfortable taking a daily pill. After absorption, oral estradiol passes through the liver before reaching systemic circulation, stimulating hepatic synthesis of sex hormone-binding globulin (SHBG), C-reactive protein, and clotting factors. This first-pass hepatic effect is why oral estrogen, but not transdermal estrogen, is associated with a 2- to 4-fold increase in venous thromboembolism (VTE) risk in case-control studies [8]. Women with a personal or family history of DVT, known thrombophilia, or obesity (BMI <30 is not a firm cutoff, but risk increases with BMI) are typically better served by transdermal routes.

Estradiol Patch

Transdermal estradiol patches deliver estradiol continuously through the skin, bypassing the liver entirely. Available doses range from 0.025 mg to 0.1 mg per day depending on the brand (Vivelle-Dot, Climara, Minivelle, and generic equivalents). Most twice-weekly patches maintain steady serum estradiol levels of 30 to 80 pg/mL at standard doses, avoiding the peaks and troughs of oral dosing. A large UK primary-care cohort (N=approximately 900,000 women) published in the BMJ found that transdermal estradiol patches were not associated with increased VTE risk, in contrast to oral estrogen preparations [8]. Patches are changed twice weekly (some formulations weekly), and skin irritation at the application site affects roughly 10 to 15 percent of users [9].

Estradiol Gel (Divigel and Others)

Divigel 0.1% estradiol gel comes in single-dose packets of 0.25 g (delivering 0.25 mg estradiol), 0.5 g (0.5 mg), and 1 g (1 mg). It is applied once daily to the upper thigh. Like the patch, it avoids hepatic first-pass metabolism and does not raise triglycerides or SHBG meaningfully. The FDA approved Divigel in 2007 for moderate to severe vasomotor symptoms of menopause; the key trial showed a statistically significant reduction in weekly hot flash frequency at 12 weeks for the 0.5 g and 1 g doses versus placebo (P<0.001) [10]. Gel formulations are particularly useful for women who develop contact dermatitis from patch adhesive. Transfer to partners or children through skin contact is a documented concern; the application site should be covered after the gel dries, typically within 2 to 5 minutes.

Estradiol Spray (Evamist)

Evamist delivers 1.53 mg of estradiol per spray applied to the inner forearm. The starting dose is one spray daily, titrated up to three sprays if symptom control is inadequate after 4 to 8 weeks. Serum estradiol levels with one spray approximate 30 pg/mL and with three sprays approximately 90 pg/mL in pharmacokinetic studies [11]. The spray format appeals to women who travel frequently or dislike adhesives and gel packets. Accidental transfer is the main safety concern; children and male partners exposed through skin contact have shown estrogen-related effects in case reports, so the forearm should not be touched until the spray has dried completely (about 2 minutes).

Common Side Effects and How to Manage Them

MPA side effects are dose-dependent and overlap considerably with symptoms attributed to HRT in general, making attribution difficult in clinical practice. The most frequently reported effects include breast tenderness, bloating, mood changes (irritability or low mood), acne, and headache. These tend to be most pronounced in the first one to three months of use and often lessen as the body adjusts.

MPA has mild androgenic and glucocorticoid activity that micronized progesterone lacks. This androgenic activity may account for the higher rates of acne and mood disruption reported with MPA compared with micronized progesterone in patient-reported outcome studies. One randomized trial (N=318) comparing MPA-based regimens to micronized progesterone found statistically significant differences in self-reported quality of life at 6 months favoring micronized progesterone, particularly for sleep and mood subscales [12].

Breakthrough bleeding is common during the first three to six months of continuous-combined MPA regimens. Persistent bleeding after six months warrants endometrial evaluation with transvaginal ultrasound and possible office biopsy to exclude hyperplasia or polyp, per the NAMS 2022 position statement [2].

Absolute Contraindications

Do not prescribe MPA or any combined HRT to women with the following conditions [4]:

• Known, suspected, or history of breast cancer
• Known or suspected estrogen- or progestogen-dependent malignancy
• Active or prior history of arterial thromboembolic disease (stroke, MI)
• Active DVT or pulmonary embolism, or prior history without anticoagulation
• Active liver disease with abnormal liver function tests
• Undiagnosed abnormal genital bleeding
• Known or suspected pregnancy

Monitoring and Follow-Up

Women starting MPA-containing HRT should have a baseline clinical breast exam and mammogram before or within 3 months of initiating therapy. Annual mammography should continue. Endometrial monitoring via transvaginal ultrasound is not required routinely for women on an adequate progestogen dose but should be performed if breakthrough bleeding persists beyond six months or if new bleeding arises after 12 months of amenorrhea on continuous-combined therapy.

Blood pressure should be measured at 3 months after HRT initiation and then annually. Oral estrogen can raise blood pressure in some women through hepatic renin substrate induction; transdermal routes are less likely to do so. If hypertension develops on oral estrogen, switching to a transdermal estradiol patch, Divigel gel, or Evamist spray is a reasonable first step before discontinuing HRT altogether [2].

A lipid panel at baseline is reasonable for any woman starting oral estrogen, given its effects on triglycerides. Transdermal routes do not require the same degree of monitoring in women without pre-existing hypertriglyceridemia.

Duration of Use and the Timing Hypothesis

The WHI enrolled women who were, on average, more than a decade past menopause. The "timing hypothesis" posits that HRT started close to the onset of menopause (the "window of opportunity," generally considered the first 10 years or before age 60) carries a more favorable risk-benefit profile than HRT started later. A re-analysis of WHI data stratified by age at initiation showed that women who began combined HRT within 10 years of menopause onset had a non-significant trend toward cardiovascular benefit, while those starting more than 20 years after menopause showed harm [13].

The NICE guideline NG23 (updated 2019) states that clinicians "should advise women that the risk of breast cancer... is increased... but that the absolute risk is small and depends on the duration of use," and that "for most women with menopausal symptoms, the benefits of HRT outweigh the risks." [14]

Duration decisions should be individualized. There is no evidence-based upper time limit that applies to all women. Annual reassessment of symptom burden, quality of life, and updated risk factors is the standard approach recommended by NAMS, NICE, and the British Menopause Society.